Mechanisms of immune regulation by IVIG

Current Opinion in Allergy and Clinical Immunology

Volumn 14, Issue 6, 2014, Pages 509-515

  Ballow, Mark ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Fc RIIB receptor; Intravenous immune globulin; Neonatal Fc receptor; Prostaglandin E; Sialylation; T regulatory cells; Th17 cells

Indexed keywords

AUTOANTIBODY; CYTOKINE; FC RECEPTOR IIB; IMMUNOGLOBULIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; LECTIN RECEPTOR; PROSTAGLANDIN E; IMMUNOLOGIC FACTOR;

AUTOIMMUNE DISEASE; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATORY DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REVIEW; SIALYLATION; T LYMPHOCYTE; TH17 CELL; ANIMAL; AUTOIMMUNE DISEASES; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ANIMALS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; PROSTAGLANDINS E; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84926618863     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000116     Document Type: Review

References (44)

1. Imbach P, Barandun S, d'Apuzzo V, et al. High dose intravenous gammaglo-bulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1:1228-2132.
2. Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmuen and inflammatory disorders. J Allergy Clin Immunol 2011; 127:315-323.
3. Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 2013; 13:176-189.
4. Junghans R, Anderson C. The protective receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci U S A 1996; 93:5512-5516.
5. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N EnglJ Med 1999; 340:227-228.
6. Li N, Zhao M, Hilario-Vargas J, et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 2005; 115:3440-3450.
7. Hansen RJ, Balthasar JP. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune throm-bycytopenia. Blood 2002; 100:2087-2093.
8. Crow AR, Song S, Freedman F, et al. IVIg-mediated amelioration of murine ITP via FcRIIB is independent of SHIP1, SHP-1, and Btk activity. Blood 2003; 102:558-560.
9. Blanchette VS, Luke B, Andrew M, et al. A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr 1993; 123:989-995.
10. Bussel J. Modulation of Fc receptor clearance and antiplatelet antibodies as a consequence of intravenous immune globulin infusion in patient with immune thrombocytopenic purpura. J Allergy Clin Immunol 1989; 84:566-578.
11. Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gammaglobulin. N Engl J Med 1982; 306:1254-1258.
12. Clarkson SB, Bussel JB, Kimberly RP, et al. Treatment of refractory immune thrombocytopenic purpura with an anti-Fcg receptor antibody. N Engl J Med 1986; 314:1236-1239.
13. Debre M, Bonnet MC, Fridman WH, et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet 1993; 342:945-949.
14. Bussel J, Pahwa S, Porges A. Changes in the vitro antibody synthesis in ITP treated with intravenous gamma globulin are closely linked to long-term outcome. J Clin Immunol 1986; 6:50-56.
15. Daeron M. Fc receptor biology. Annu Rev Immunol 1997; 15:203-234.
16. Kimberly RP, Salmon JE, Edberg JC. Receptors for immunoglobulin G. Arthritis Rheum 1995; 38:306-314.
17. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291:484-486.
18. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immuno-globulin G resulting from Fc sialylation. Science 2006; 313:670-673.
19. Anthony RM, Nimmerjahn F, Ashline D, et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008; 320:373-376.
20. Arnold J, Wormaild M, Sim R, et al. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol 2007; 25:21-50.
21. Anthony RM, Wermeling F, Karlsson M, Ravetch J. Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A 2008; 105:19571-19578.
22. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. Intravenous gammaglo-bulin suppresses inflammation through a novel T(H)2 pathway. Nature 2011; 475:110-113.
23. Leontyev D, Katsman Y, Ma XZ, et al. Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin. Transfusion 2012; 52:1799-1805.
24. Schwab I, Biburger M, Kronke G, et al. IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1. Eur J Immunol 2012; 42:826-830.
25. Tjon AS, van Gent R, Jaadar H, et al. Intravenous Immunoglobulin Treatment in Humans Suppresses Dendritic Cell Function via Stimulation of IL-4 and IL-13 Production. J Immunol 2014; 192:5625-5634.
26. Bayry J, Bansal K, Kazatchkine M, Kaveri S. DC-SIGN and a2,6-sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A 2009; 106:E24.
27. Yu X, Vasiljevic S, Mitchell DA, et al. Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain. J Mol Biol 2013; 425:1253-1258.
28. Tackenberg B, Jelcic I, Baerenwaldt A, et al. Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U S A 2009; 106:4788-4792.
29. Campbell IK, Miescher S, Branch DR, et al. Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils. J Immunol 2014; 192:5031-5038.
30. Martin P, Talabot-Ayer D, Seemayer CA, et al. Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency. Arthritis Res Ther 2013; 15:R13.
31. Guhr T, Bloem J, Derksen NI, et al. Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia. PLoS One 2011; 6:e21246.
32. Kasermann F, Boerema DJ, Ruegsegger M, et al. Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation. PLoS One 2012; 7:e37243.
33. Othy S, Hegde P, Topcu S, et al. Intravenous gammaglobulin inhibits ence-phalitogenic potential of pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine-1 phosphate receptor 1-mammalian target of rapamycin axis. J Immunol 2013; 190:4535-4541.
34. Othy S, Topcu S, Saha C, et al. Sialylation may be dispensable for reciprocal modulation of helper T cells by intravenous immunoglobulin. Eur J Immunol 2014; 44:2059-2063.
35. Trinath J, Hegde P, Sharma M, et al. Intravenous immunoglobulin expands regulatory T cells via induction of cyclo-oxygenase-2-dependent prostaglan-din E2 in human dendritic cells. Blood 2013; 122:1419-1427.
36. Wiedeman A, Santer D, Wei Y, et al. Contrasting mechanisms of interferon-a inhibition by intravenous immunoglobulin after induction by immune complexes versus toll-like receptor agonists. Arthritis Rheum 2013; 65:2713-2723.
37. Kaufman GN, Massoud AH, Audusseau S, et al. Intravenous immunoglobulin attenuates airway hyperresponsiveness in a murine model of allergic asthma. Clin Exp Allergy 2011; 41:718-728.
38. Massoud AH, Guay J, Shalaby KH, et al. Intravenous immunoglobulin attenuates airway inflammation through induction of forkhead box protein 3-positive regulatory T cells. J Allergy Clin Immunol 2012; 129:1656-1665.e3.
39. Massoud AH, Yona M, Xue D, et al. Dendritic cell immunoreceptor: a novel receptor for intravenous immunoglobulin mediates induction of regulatory T cells. J Allergy Clin Immunol 2014; 133:853-863.e5.
40. De Groot A, Moise L, McMurry J, et al. Activation of natural regulatory T cells by IgG Fc-derived peptide 'Tregitopes'. Blood 2008; 112:3303-3311.
41. Olivito B, Taddio A, Simonini G, et al. Defective FoxP3 expression in patients with acute Kawasaki disease and restoration by intravenous immunoglobulin therapy. Clin Exp Rheumatol 2010; 28:93-97.
42. Tsurikisawa N, Saito H, Oshikata C, et al. High dose intravenous immuno-globulin treatment increases regulatory T cells in patients with eosinophilic granulomatosis with polyangitis. J Rheumatol 2012; 39:1019-1025.
43. Tjon A, Tha-In T, Metselaar H, et al. Patients treated with high-dose intravenous immunoglobulin show selective activation of regulatory T cells. Clin Exp Immunol 2013; 173:259-267.
44. Maddur MS, Vani J, Hegde P, et al. Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin. J Allergy Clin Immunol 2011; 127:823-830; e1-7.